Exome Asset Management LLC Makes New Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

Exome Asset Management LLC acquired a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 120,165 shares of the company’s stock, valued at approximately $5,274,000. Structure Therapeutics accounts for 3.5% of Exome Asset Management LLC’s investment portfolio, making the stock its 4th largest position. Exome Asset Management LLC owned 0.21% of Structure Therapeutics as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in GPCR. Wellington Management Group LLP grew its holdings in Structure Therapeutics by 2.9% in the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after buying an additional 221,851 shares during the period. FMR LLC grew its holdings in Structure Therapeutics by 6.7% in the third quarter. FMR LLC now owns 6,128,444 shares of the company’s stock valued at $268,977,000 after purchasing an additional 383,635 shares during the period. Janus Henderson Group PLC grew its holdings in Structure Therapeutics by 18.0% in the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock valued at $173,623,000 after purchasing an additional 602,609 shares during the period. Driehaus Capital Management LLC increased its position in Structure Therapeutics by 3.5% during the second quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock worth $101,204,000 after purchasing an additional 86,833 shares during the last quarter. Finally, Federated Hermes Inc. raised its stake in Structure Therapeutics by 6.6% during the second quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company’s stock worth $94,531,000 after purchasing an additional 150,000 shares during the period. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Performance

NASDAQ:GPCR opened at $31.25 on Friday. Structure Therapeutics Inc. has a one year low of $26.61 and a one year high of $62.74. The business’s 50-day simple moving average is $36.32 and its 200 day simple moving average is $39.18. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of -42.23 and a beta of -3.41.

Analysts Set New Price Targets

Several brokerages have recently issued reports on GPCR. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a research note on Monday, September 23rd. HC Wainwright initiated coverage on Structure Therapeutics in a research note on Wednesday, December 4th. They set a “buy” rating and a $80.00 price target for the company. Finally, Morgan Stanley initiated coverage on Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price for the company. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $85.67.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.